Clinical Trial Update: Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination [Phase 3]

View source ↗

Summary

An update on a Phase 3 long-term follow-up trial evaluating the safety and immunogenicity of PXVX0317 as a single-dose or booster vaccination for Chikungunya vi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chikungunya Virus Infection

Drugs mentioned

• PXVX0317 (CHIKV VLP Vaccine)

Snippet

Sponsor: Bavarian Nordic | Conditions: Chikungunya Virus Infection | Phase 3 | Status: ACTIVE_NOT_RECRUITING